21 results
DRS/A
EX-10.9
KPRX
Kiora Pharmaceuticals Inc
8 Jul 14
Draft registration statement (amended)
12:00am
Termination
If your Service terminates for any reason except death or total and permanent disability, then this option, to the extent vested … of death.
Disability
If your Service terminates because of your total and permanent disability, then this option will expire at the close of business
8-K
EX-10.1
KPRX
Kiora Pharmaceuticals Inc
24 Mar 20
Departure of Directors or Certain Officers
4:15pm
to the Employee. Upon the death of the Employee or the Employee’s disability such that she is unable to perform her duties as determined, in good faith … ) or (ii) the Employee’s employment hereunder terminates by reason of her death or disability or (iii) the Employer terminates the employment of the Employee
8-K
EX-10.3
KPRX
Kiora Pharmaceuticals Inc
1 Feb 21
Departure of Directors or Certain Officers
6:55am
. or (iii) by the Employee’s death or disability such that he is unable to perform his duties as determined, in good faith, by the Board of Directors … by the Board of Directors of the Employer (other than as a result of the Employee’s death or disability), in each case after the Employer has provided
8-K
EX-10.2
KPRX
Kiora Pharmaceuticals Inc
1 Feb 21
Departure of Directors or Certain Officers
6:55am
obligations towards the Company and EyeGate (other than as a result of his death or disability) and the reasons listed in Section 27 of the Austrian
8-K
EX-10.1
m62f720j01 ykfe
26 Jul 21
EyeGate Pharmaceuticals Announces Appointment of Brian M. Strem, Ph.D., as President and Chief Executive Officer
4:18pm
8-K
EX-10.1
3lflwmt
1 Feb 21
Departure of Directors or Certain Officers
6:55am
8-K
EX-10.1
80pthejusj66htyrb
1 Feb 22
Kiora Pharmaceuticals Appoints Erin Parsons to its Board of Directors; Stephen From to Retire from Board
6:45am
8-K
EX-10.1
voeidarhcy5nxtt19v
26 Oct 21
EyeGate adds Bayon Therapeutics’ portfolio of vision-restoring small molecules to its development pipeline
7:00am
8-K
EX-2.1
jlqu03umikdxnjeadxl
26 Oct 21
EyeGate adds Bayon Therapeutics’ portfolio of vision-restoring small molecules to its development pipeline
7:00am
8-K
EX-2.1
8r6tb44vnst ult
21 Dec 20
EyeGate Pharma Announces Transformative Acquisition of Panoptes Pharma
6:55am
PRE 14A
73w1bf b3jwh
17 May 18
Preliminary proxy
5:21pm